Grade: Research grade

Factory Location: Hangzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe, Australasia,Asia,Middle East,Africa

Monthly Production Capacity: hundreds of grams

Packaging Information: 500mg,1g, 10g,50g 100g per package with icebag

Delivery Lead Time: In stock or 2-3weeks

Sample Provided: yes

Payment Terms: T/T

Cilengitide is a cyclic peptide containing the RGD sequence. The peptide is based on the in vivo αv β3 integrin ligand, and is obtained through a comprehensive use of cyclization, spatial screening and methylation scanning, and has high affinity and selectivity for αv β3 integrin. Tests have shown that the peptide not only can better inhibit the growth of melanoma and glioma, but also can improve the cure rate of other tumors such as head and neck squamous cell tumors when combined with radiotherapy. It has a good market prospect and potential. In peptide synthesis, Cilengitide is produced through a combination of solid-phase peptide synthesis technology and liquid-phase peptide synthesis technology.